Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALT

Altimmune Inc

Feb 04 • 04:00PM ET

6.64

Dollar change +0.20
Percentage change 3.11	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: VTI IWM XBI VXF IBB VTWO IWO IWN VHT PTH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	0.92%	Shs Outstand	71.12M	Perf Week	-4.18%
Market Cap	472.26M	Forward P/E	-	EPS next Y	-1.49	Insider Trans	-2.39%	Shs Float	70.47M	Perf Month	-6.61%
Income	-103.52M	PEG	-	EPS next Q	-0.34	Inst Own	55.99%	Short Float	34.90%	Perf Quarter	-1.48%
Sales	0.05M	P/S	9445.30	EPS this Y	18.37%	Inst Trans	-6.54%	Short Ratio	7.47	Perf Half Y	10.67%
Book/sh	1.88	P/B	3.54	EPS next Y	-9.70%	ROA	-65.84%	Short Interest	24.59M	Perf Year	-32.79%
Cash/sh	1.96	P/C	3.39	EPS next 5Y	1.35%	ROE	-72.96%	52W Range	5.28 - 14.84	Perf YTD	-7.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.74%	ROI	-76.77%	52W High	-55.26%	Beta	0.86
Dividend TTM	-	Quick Ratio	16.87	Sales past 5Y	154.97%	Gross Margin	-3928.85%	52W Low	25.88%	ATR (14)	0.43
Dividend Ex-Date	Jan 20, 2017	Current Ratio	16.87	EPS Y/Y TTM	-1.24%	Oper. Margin	-191365.38%	RSI (14)	40.90	Volatility	5.12% 5.36%
Employees	59	Debt/Eq	0.01	Sales Y/Y TTM	-81.36%	Profit Margin	-199076.92%	Recom	1.22	Target Price	22.25
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	16.61%	Payout	-	Rel Volume	0.41	Prev Close	6.44
Sales Surprise	614.29%	EPS Surprise	10.26%	Sales Q/Q	-98.62%	Earnings	Nov 12 BMO	Avg Volume	3.29M	Price	6.64
SMA20	-3.38%	SMA50	-14.71%	SMA200	-7.06%	Trades		Volume	1,356,447	Change	3.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
07:30AM	Loading…
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
08:00AM	Loading…
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
11:08PM	Loading…
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
Jun-22-24 04:45PM	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions (GlobeNewswire)
Jun-21-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) +7.91%
Jun-20-24 07:30AM	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways (GlobeNewswire)
Jun-18-24 07:30AM	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
Jun-05-24 07:00AM	Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 07:31AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024 (GlobeNewswire)
May-27-24 02:56PM	The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop (InvestorPlace)
May-23-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) -6.34%
May-21-24 02:53PM	Altimmune, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALT (GlobeNewswire)
09:00AM	Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) (PR Newswire)
May-20-24 03:01PM	Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights (Business Wire)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace) -10.00%
May-15-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire) +13.43%
May-14-24 12:47PM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights ALT (GlobeNewswire) +6.11%
May-10-24 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 03:07PM	Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report (InvestorPlace) -18.65%
Jan-02-24 07:30AM	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 (GlobeNewswire) -6.49%
Dec-01-23 11:45AM	Why Is Altimmune (ALT) Stock Up 43% Today? (InvestorPlace) +12.97%
04:47AM	Altimmune, seeking edge on Lilly and Novo, puts heart health at center of phase 2 obesity data drop (FierceBiotech.com)
Nov-30-23 04:24PM	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide (GlobeNewswire)
Nov-08-23 09:15AM	Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:00AM	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-31-23 07:30AM	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (GlobeNewswire)
Oct-26-23 07:30AM	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Oct-25-23 07:30AM	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-17-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-12-23 07:30AM	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +7.41%
Aug-30-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +6.96%
Jun-16-23 07:30AM	Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023 (GlobeNewswire)
May-31-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-11-23 07:00AM	Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +7.03%
May-08-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-04-23 07:30AM	Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (GlobeNewswire)
Apr-11-23 07:30AM	Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B (GlobeNewswire)
Mar-27-23 04:05PM	Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors (GlobeNewswire) +11.57% -8.30%
Mar-21-23 07:00AM	Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial (GlobeNewswire) -54.67%
Feb-28-23 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update (GlobeNewswire) +6.42%
Feb-21-23 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.27%

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Feb 01 '25	Option Exercise	0.00	16,545	0	351,645	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Jan 30 '25	Option Exercise	0.00	26,775	0	342,696	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	78,898	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	74,000	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	69,562	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	62,921	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	57,910	Jan 28 09:06 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	36,150	Jan 28 09:05 PM
Harris Matthew Scott	Chief Medical Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	69,719	Jan 28 09:05 PM
Garg Vipin K	President and CEO	Jan 25 '25	Option Exercise	0.00	42,050	0	334,078	Jan 28 09:04 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '25	Option Exercise	0.00	9,375	0	24,035	Jan 03 04:40 PM
Drutz David	Director	Aug 19 '24	Option Exercise	2.55	41,750	106,375	63,708	Aug 20 06:05 PM
Drutz David	Director	Aug 19 '24	Sale	6.90	16,011	110,547	41,958	Aug 20 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your FINVIZ experience